Health
Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases – Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 …
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients.
What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday.
The committee recommended continuing the enrollment of hospitalized…
-
General15 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News24 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News16 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
Noosa News14 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba